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Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis of unknown origin. Its autoim-
mune origin has been suggested but never proven. Several reports have implicated Klebsi-
ella pneumoniae as a triggering or perpetuating factor in AS; however, its role in the disease
pathogenesis remains debated. Moreover, despite extensive investigations, a biomarker for
AS has not yet been identified. To clarify these issues, we screened a random peptide library
with pooled IgGs obtained from 40 patients with AS. A peptide (AS peptide) selected from
the library was recognized by serum IgGs from 170 of 200 (85%) patients with AS but not by
serum specimens from 100 healthy controls. Interestingly, the AS peptide shows a
sequence similarity with several molecules expressed at the fibrocartilaginous sites that are
primarily involved in the AS inflammatory process. Moreover, the peptide is highly homolo-
gous to a Klebsiella pneumoniae dipeptidase (DPP) protein. The antibody affinity purified
against the AS peptide recognizes the autoantigens and the DPP protein. Furthermore,
serum IgG antibodies against the Klebsiella DPP121-145 peptide epitope were detected in
190 of 200 patients with AS (95%), 3 of 200 patients with rheumatoid arthritis (1.5%) and
only 1 of 100 (1%) patients with psoriatic arthritis. Such reactivity was not detected in healthy
control donors. Our results show that antibodies directed against an epitope of a Klebsiella
pneumoniae-derived protein are present in nearly all patients with AS. In the absence of
serological biomarkers for AS, such antibodies may represent a useful tool in the diagnosis
of the disease.
Introduction
Ankylosing spondylitis (AS) is one of the most important forms of chronic inflammatory
arthritis and represents the “prototype” of a group of interrelated diseases known as spondy-
loarthritides (SpA). The disease affects primarily the spine, the sacroiliac joints and the periph-
eral enthesis and joints [1,2]. However, extra-articular manifestations, such as acute anterior
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uveitis, psoriasis and inflammatory bowel disease, and mainly Crohn’s disease, may be present
in nearly half the patients [3].
The class I surface antigen HLA-B27 is associated with the disease, and although the basis
of this association remains unclear [3], it seems that aberrant features of HLA-B27 may be
involved in the abnormal behaviour of antigen-presenting cells [4,5]. Genome-wide associa-
tion studies have identified genes involved in the interleukin-23-interleukin-17 pathway that
are able to confer susceptibility to AS [6]. Among the other genes found to be associated with
the disease, the gene encoding for the aminopeptidase ERAP1 seems to be particularly interest-
ing since the enzyme trims peptides of the appropriate length for binding to MHC class I mol-
ecules as follows: gene polymorphisms encode for variants of ERAP1 with different functional
activity and interaction with HLA-B27 [7].
The diagnosis of AS is based on a clinical examination and the exclusion of other types of
seronegative arthritis. The medical history, physical examination, blood tests, and imaging of
the joints may be used for diagnostic purposes. There is no definitive diagnostic test for AS,
and, therefore, the identification of a biochemical or immunological test with a high sensitivity
and specificity for the diagnosis and follow-up of patients with AS is an important goal in
medicine.
The presence of autoantibodies, which are detectable in many rheumatic diseases, is not a
typical feature of AS. Antibodies directed against leukocytes [8], neutrophils [9], and some col-
lagen proteins have been previously described [10]. More recently, Wright C. et al. [11] have
shown the presence of multiple autoantibodies directed against proteins expressed in connec-
tive and skeletal tissue in approximately 40% of patients with AS using a nucleic acid program-
mable protein array. Nevertheless, autoantibodies typically associated with AS have not, thus
far, been identified.
Another aspect of AS that needs to be clarified is the relationship between Klebsiella pneu-
moniae and the aetiopathogenesis of the disease.
A large body of evidence based on genetic, microbiological, molecular and immunological
studies suggests that Klebsiella pneumoniae is the main microbial agent implicated in the aetio-
pathogenesis of AS, as a triggering and/or a perpetuating factor [12–14], possibly through a
mechanism of molecular mimicry with self-antigens. However, the precise role played by Kleb-
siella pneumoniae in the disease remains controversial and has not yet been clarified.
We aimed to identify a potential serologic marker that may help in the diagnosis and/or
monitoring of disease activity in patients with AS. For this purpose, we have used a molecular
biological approach, which has been successfully applied to other immune-mediated diseases
[15–18].
Materials and Methods
Patients
Serum samples from patients and healthy controls were obtained between January 2005 and
November 2013. All samples were stored at −20˚C. Blood samples were collected after obtain-
ing written informed consent. The present study was approved by the local ethics committee of
the Azienda Ospedaliera Universitaria of Verona, Verona, Italy. We analysed a cohort of 200
patients (165 males and 35 females, mean age: 47±14 years) affected by AS, attending the Unit
of Autoimmune Diseases at the University Hospital of Verona and the Rheumatology Depart-
ment of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera.
The diagnosis of AS was assessed following the modified Criteria of New York [19]. The clinical
features of the 200 patients were as follows: sacroiliitis or spondylitis was present in all the sub-
jects, and peripheral joint arthritis was present in 63/200 patients. Eye involvement was present
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in 57/200 subjects, and cardiac involvement was present in 4/200 patients. Crohn’s disease was
present in 10/200 patients. The HLA B27 allele was detected in 189/200 patients.
A group of 100 patients (64 males and 36 females, mean age: 57±14 years), affected by psori-
atic arthritis (PsA), was also studied. All patients fulfilled the Classification Criteria for Psori-
atic Arthritis (CASPAR) criteria for the classification of PsA [20]. Two hundred patients with
rheumatoid arthritis (RA) were also included in the study. RA patients fulfilled the American
College of Rheumatology classification criteria for RA [21]. All patients were consecutively
enrolled, regarding of the disease activity and treatment.
One hundred age- and sex-matched healthy donors served as the control group.
All the investigations were carried out according to the principles expressed in the Helsinki
Declaration.
Peptide Library
The screening procedure for the peptide library has been described in detail elsewhere [15–
18]. Briefly, a random dodecamer peptide library, which expresses peptides on the surface of
Escherichia coli, was screened with pooled purified immunoglobulins obtained from the serum
samples of 40 patients with AS, according to the manufacturer’s instructions (FliTrx Panning
Kit, Invitrogen). Following five rounds of biopanning experiments, the enriched library was
grown, and single colonies were induced with tryptophan. Bacteria were then lysed in sample
buffer and tested by Western blotting with the pooled immunoglobulin fraction obtained from
the patients with AS to identify positive clones. DNA was then extracted and sequenced. A set
of 15 out of the 27 peptides derived from the last biopanning round was synthetized and
employed in a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) to test
serum samples from individual patients.
Peptide Synthesis
All the synthetic peptides, including the AS peptide (RIGHVGARPSRH), the Klebsiella pneu-
moniae-derived proline dipeptidase (DPP) peptide (IGYIGPVPER) and the DPP121-145 peptide
(AARGNIGYIG PVPERALGLG IAADK), the perlecan (PER) peptide (VGTRPSNH), the
ADAMTSL3/punctin 2 (ADM) peptide (GHLGARIQR), the Arf GAP With SH3 Domain, the
Ankyrin Repeat And PH Domain (ASAP1) peptide (IGHIEGQPSR) and the irrelevant control
peptide (VTLPKDSDVELP), were manually synthesized using the standard method of solid-
phase peptide synthesis; this method employs the 9-fluorenylmethoxycarbonyl strategy with
minor modifications [22].
Affinity Purification of Anti-Peptide Antibodies
The peptides (5 mg peptide per gram of dried Sepharose powder) were coupled to Sepharose
4B (Pharmacia) following the manufacturer’s instructions. Sera diluted in PBS were applied to
the columns. Eluted Igs were dialyzed against PBS. The purity of the preparations was checked
by SDS-PAGE followed by silver staining.
Assessment of Antibody Binding
a) DELFIA assay. The DELFIA assay is a time-resolved fluorescence method that is com-
monly used to study antibody interactions with solid-phase proteins or peptides. The method
has been described in detail elsewhere [17]. Briefly, the peptides (20 micrograms per millilitre)
were used to coat DELFIA plates (PerkinElmer, Waltham, Ma, USA). The plates were then
blocked for 1 hour with a commercially available blocking reagent (PerkinElmer). The sera
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were diluted in phosphate-buffered saline plus 1% bovine serum albumin (Sigma) and incu-
bated on the plates overnight at 4 to 8˚C. The plates were washed 10 times with washing buffer
(PerkinElmer), and bound antibodies were detected using a europium-labelled anti-human
IgG antiserum (1:500 in diluting buffer, PerkinElmer). Plates were read on a Victor3 instru-
ment (PerkinElmer), and the data were analysed with software supplied along with the DEL-
FIA instrument. Absorbance values higher than the mean (+3 SD) for each serum dilution of
the control group were considered positive.
b) ELISA assay. The ELISA assay for the binding of antibodies to collagen type I and II
was performed using commercially available kits (CHONDREX, Inc., Redmond, WA, USA).
In the ELISA assay, for the detection of anti-fibronectin antibodies, plates (Immulon 2HB
Thermo Scientific, Illkirch, France) were coated with 10 μg/ml of human fibronectin (SIGMA,
St. Louis, MO, USA), and the tested antibodies were diluted in PBS 1% BSA and incubated
overnight at 4˚C. Plates were washed 3 times with PBS 1% Tween and one time with PBS
alone. Alkaline phosphatase-labelled anti-human IgG antibodies were purchased from Sigma.
IgG antibodies to Klebsiella pneumoniae were detected by ELISA using a bacterial extract
adsorbed on the solid phase as described in detail elsewhere [23]. For the binding to recombi-
nant Klebsiella pneumoniae, proline dipeptidase (MyBioSource, San Diego, CA, USA) plates
were coated with 20 microgram/ml of recombinant protein in PBS. The test was then per-
formed as described above. The binding to the other two Klebsiella pneumoniae-derived pro-
teins was assessed using the two synthetic peptides (LFI and SET peptide) using DELFIA as
described above.
c) Western Blotting. The antibody binding to the Arf GAP with the SH3 Domain,
Ankyrin Repeat and PH Domain (ASAP1) protein was tested using the recombinant ASAP1,
(OriGene Inc., Rockville, MD, USA) using an immunoblot assay. The blots were probed with
primary antibodies (human anti-peptide antibodies or mouse control monoclonal antibody)
followed by either peroxidase-conjugated anti-human immunoglobulin antibodies or mouse
IgG antibodies (Sigma) (10 μg per millilitre). A monoclonal antibody against ASAP1 was pur-
chased from OriGene and used as a positive control. A monoclonal antibody directed against
beta-actin was used as an equal loading control (Abcam).
The blots were developed using chemiluminescence according to the manufacturer’s
instructions (Thermo Scientific).
Statistical Analysis
We evaluated the sensitivity and specificity of the assay with the use of receiver-operating-
characteristic (ROC) curve analysis, which evaluates the area under the curve (AUC) with 95%
confidence intervals. Statistical analysis was carried out using SPSS Software, Version 20
(SPSS).
Results
Peptide Library
We screened a peptide library with pooled Igs obtained from a group of 40 patients with AS. A
set of 13 peptides, out of the 26 peptides derived from the last panning step, was used to screen
patients’ sera in a DELFIA assay employing the solid phase peptide. We identified a peptide
(AS peptide: RIGHVGARPSRH) that was specifically recognized by IgG of serum samples
from 33 of 40 patients with AS (83%) (absorbance (mean ± s.d.): 41.900 ± 12.822 for a serum
dilution of 1:100) but not by serum IgG from healthy subjects. The results were then validated
in another cohort of 160 patients with AS, who were not included in the group used for the
library screening. Anti-AS peptide antibodies were found in 137/160 patients; by combining
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the two cohorts of patients, we observed that 170/200 (85%) patients’ sera contained IgG anti-
bodies directed against the AS peptide. These data indicate that this peptide sequence (AS pep-
tide) contains an epitope, which is recognized by the sera of most patients with AS.
Autoantigen Targets in Ankylosing Spondylitis
We next compared the AS peptide sequence with human proteins in a protein data bank
(SWISS-PROT database of known human sequences), using BLASTP software (NCBI BLAST
network service), and we observed that the AS peptide shared homology with different pro-
teins highly expressed at the fibrocartilaginous sites, which are primarily affected in the course
of AS. These autoantigens include type I and II collagens (in particular, collagen alpha-1 XXIV
[24], collagen alpha-1 XXI [25], and collagen alpha-2 XI, which are particularly abundant at
cartilaginous sites [26]), heparan sulphate proteoglycan 2, also known as perlecan, two glyco-
proteins particularly represented in the extracellular matrix, fibronectin and ADAMTSL3/
punctin 2 [27,28], and a protein involved in cytoskeleton remodelling, named ArfGAP with
SH3 domain, ankyrin repeat and PH domain 1 actin (ASAP1) [29] (Fig 1).
Fig 1. Peptides used in the study and sequence homologies. Sequence homology between the AS
peptide and self-proteins (colons indicate identity and asterisks indicate conservative substitutions).
doi:10.1371/journal.pone.0171073.g001
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Affinity-purified antibodies against the AS peptide isolated from the sera of 10 patients with
AS specifically recognized these molecules (Fig 2A–2F). Indeed, anti-AS peptide antibodies
bound collagen type I (Fig 2A), collagen type II (Fig 2B) and fibronectin (Fig 2C) in ELISA.
Since the recombinant version of human perlecan and ADAMTSL3/punctin 2 molecules
was not available, the cross-reaction of anti-AS peptide antibodies with these proteins was
Fig 2. Binding of anti-peptide antibodies to autoantigens. Binding of affinity purified anti-AS peptide
antibodies to collagen type I (A), collagen type II (B), fibronectin (C), PER peptide (D), ADM peptide (E). Black
continous line: antibodies affinity purified against the AS peptide from the sera of patients affected by AS.
Dotted line: antibodies affinity purified against an irrelevant control peptide. A, B and C: ELISA assay. D and
E: DELFIA assay. X axis: increasing antibody concentration by two fold ranging from 1.25 microgram/ml to 10
microgram/ml. Y axis: Optical Density values obtained at 405 nm wavelength for ELISA assay and IgG
international units for DELFIA assay. F: western blot analysis of the binding of anti-peptide antibodies to
ASAP1(molecular weight 125 KDa). Lane 1 and 2, antibodies affinity purified against an irrelevant control
peptide probed with cell lysate from cells transfected with ASAP1 (lane 1) or from untransfected cells (lane 2);
lane 3 and 4, antibodies affinity purified against the AS peptide probed with cell lysate from cells transfected
with ASAP1 (lane 3) or from untransfected cells (lane 4); lanes 5 and 6, commercially available monoclonal
antibody directed against ASAP1, probed with cell lysate from cells transfected with ASAP1 (lane 5) or from
untransfected cells (lane 6). Lower panel of Fig 2F: immunoblot with actin demonstrates equal protein loading.
doi:10.1371/journal.pone.0171073.g002
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assessed with a DELFIA assay, in which the synthetic peptides (PER and ADM peptides, see
above) had been used, as solid phase antigens to coat the DELFIA plates (Fig 2D and 2E). The
binding of anti-AS peptide antibodies to ASAP1 was assessed using a cell line (HEK293T)
overexpressing the molecule. Antibodies directed against the AS peptide specifically recog-
nized the ASAP1 molecule; in contrast, affinity- purified antibodies directed against an irrele-
vant control peptide did not react with the ASAP1 protein (Fig 2F). Altogether, these results
show that sera of patients with AS contain IgG antibodies able to cross-react with several pro-
teins expressed at the fibrocartilaginous sites that are preferential targets of inflammatory
aggression in AS.
Klebsiella pneumoniae and Ankylosing Spondylitis
Since Klebsiella pneumoniae has been associated with AS [12], we decided to compare the AS
peptide sequence with known microbial protein sequences in a protein data bank (SWIS-
S-PROT database), using BLASTP software from the Basic Local Alignment Search Tool
(BLAST) network service of the National Center for Biotechnology Information (NCBI). We
observed that the AS peptide shares some degree of homology with 3 Klebsiella pneumoniae–
derived proteins (Fig 3A). Antibodies purified against the AS peptide bound the sugar trans-
porter (SET) peptide (Fig 3B) and the L-fucose peptide (Fig 3C) in DELFIA assay and recog-
nized the recombinant dipeptidase (DPP) protein (Fig 3D). We next used the 3 bacterial
peptides in DELFIA to test a panel of 50 sera from AS patients. Antibodies directed against the
Klebsiella pneumoniae DPP peptide were detected in 36/50 (72%) serum samples; while anti-
bodies against the Klebsiella pneumoniae SET and the Klebsiella pneumoniae L-fucose isomer-
ase were detected at a lower frequency (37% and 25% of the patients, respectively). Based on
these results, we decided to focus our attention on the Klebsiella pneumoniae-derived DPP
protein. We, therefore, used the recombinant version of the DPP molecule to test a panel of
100 sera from AS patients using a DELFIA assay. Serum IgG antibodies against the Klebsiella-
derived DPP protein were detected in 88 out of 100 patients with AS, but not in control
healthy donors. However, since serum IgG antibodies against the Klebsiella-derived peptide
(IGYIGPVPER) were detected only in 70 out of 100 patients with AS, we reasoned that the
Klebsiella-derived DPP protein could contain other crucial epitopes for the anti-Klebsiella
pneumoniae antibody response.
We, therefore, decided to precisely map the reactivity of AS serum antibodies against the
Klebsiella Pneumoniae-derived proline dipeptidase protein using 25 amino acids-long syn-
thetic peptides spanning the entire DPP sequence and found that 190 out of the 200 patients
with AS had serum IgG antibodies against the peptide DPP121-145 (AARGNIGYIGPVPERALG
LGIAADK). Interestingly, the ten patients who resulted negative for the presence of anti-
DPP121-145 IgG antibodies were HLA-B27 negative.
Anti-peptide antibodies were also investigated in two other inflammatory arthritides, RA
and PsA, and these antibodies were present in 3 out of the 200 patients with RA (1.5%) and
only in 1 out of the 100 (1%) patients with PsA (Fig 4A).
The sensitivity and specificity of the quantitative analysis of the assay in discriminating AS
from healthy donors, with a cut-off value of 32,250 international units, was 95% and 100%,
respectively. The area under the curve (AUC) in the ROC analysis was 0.99 (95% confidence
interval [Cl] 0.9824 to 0.9990; P<0.0001) (Fig 4B).
The ROC curves obtained, by comparing AS serum specimens with RA and PsA samples,
are shown in Fig 4C and 4D. These data show that antibodies directed against a peptide epi-
tope of the Klebsiella pneumoniae–derived protein DPP are typically present in the sera of
patients with AS.
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Discussion
We report here on a serologic marker that is present in nearly all patients with AS.
In clinical practice, the diagnosis of AS is based on the clinical history, physical examination
and imaging, and thus far, there are no biomarkers available to help in the diagnostic process.
Moreover, despite extensive investigations, the autoantibodies typically associated with AS and
present in the patients’ sera at a high frequency have not been identified thus far, leading to the
hypothesis that AS may be an autoinflammatory rather than an autoimmune disease. Indeed,
autoantibodies directed against either collagen or neutrophils or nuclear antigens [8–10] have
Fig 3. Anti- peptide antibodies bind Klebsiella pneumoniae-derived proteins. (A) Sequence homology between
the AS peptide and the Klebsiella pneumoniae-derived proteins: sugar transporter (SET) protein, Xaa-Pro dipeptidase
(DPP) protein and L-fucose isomerase (LFI) protein. Binding of affinity purified anti-AS peptide antibodies (black
continuous line) to the SET (B) and LFI (C) peptide in DELFIA. Binding of affinity purified anti-AS peptide antibodies to
recombinant DPP protein in ELISA (D). Dotted line: antibodies affinity purified against an irrelevant control peptide. X
axis: increasing antibody concentration by two fold ranging from 1.25 microgram/ml to 10 microgram/ml. Y axis: IgG
international units for DELFIA assay and Optical Density values obtained at 405 nm wavelength for ELISA assay.
doi:10.1371/journal.pone.0171073.g003
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been detected in a few cases, and, in a recent report, which employed a proteomic approach
[11], antibodies directed against self-antigens could be found only in 44% of the sera studied.
Using a peptide library approach, we could identify a peptide, the AS peptide, which is spe-
cifically recognized by 85% of the sera of patients with AS but is not detectable in the sera of
healthy controls.
The peptide shared similarity with different proteins present within the fibrocartilaginous
sites that are primarily affected in the course of AS. These autoantigens include type I and II
collagens (in particular, collagen alpha-1 XXIV [24], collagen alpha-1 XXI [25], and collagen
alpha-2 XI, which is particularly abundant at cartilaginous sites [26]), the heparan sulphate
proteoglycan 2, also known as perlecan, two glycoproteins particularly represented in the
extracellular matrix, fibronectin and ADAMTSL3/punctin 2 [27,28], and a protein involved in
cytoskeleton remodelling, ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 actin
(ASAP1) [29].
Fig 4. Antibodies directed against the Klebsiella pneumoniae-derived DPP121-145 peptide in the sera of patients with
inflammatory arthritides. (A) The results of an assay of europium-labeled antihuman IgG antibodies are shown; each circle
represents a measurement for one patient, and the dashed horizontal line indicates the cut-off value of 32,250 international
units. ROC curves showing sensitivity and specificity of the assay of IgG antibodies against the Klebsiella pneumoniae-
derived DPP121-145 peptide for differentiating between AS sera and l healthy donors (B), between AS samples and RA (C) and
between AS sera and PsA samples (D).
doi:10.1371/journal.pone.0171073.g004
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A possible role for Klebsiella pneumoniae in the pathogenesis of AS has been reported [12–
14], and although still controversial, this infectious agent is the only one that has been linked
with AS. In this study, we found that the AS peptide, which we identified by screening a pep-
tide library with sera from patients with AS, shares similarity with an amino acid sequence of
the DPP protein of Klebsiella pneumoniae. Interestingly, compared to the frequency of anti-
bodies directed against the AS peptide, antibodies directed against the DPP121-145 peptide were
detectable at an even higher frequency in AS serum samples (85% versus 95%, respectively).
This difference may be related to the length of the DPP121-145 peptide that could allow the
acquisition of a tridimensional structure.
It is worthwhile mentioning that the patients who did not show antibodies directed against
the DPP121-145 peptide were HLA-B27 negative, suggesting a relationship between HLA-B27
and the ability to mount an immune response against Klebsiella pneumoniae-derived antigens
that is cross-reactive with autoantigens. Indeed, the AS peptide has arginine residues that
could allow a potential binding to HLA-B27 antigen; it will be of great interest to test the bind-
ing of the AS peptide to HLA-B27 antigen for its implication in the previously mentioned
cross-reactive immune response.
Moreover, it is noteworthy mentioning that the anti-Klebsiella pneumoniae-derived peptide
antibodies are nearly absent in sera of patients affected by PsA and RA and are not detected in
healthy donors.
Although these results do not clarify the role played by Klebsiella pneumoniae in the disease
pathogenesis, the ability of purified anti-AS peptide antibodies to recognize both autoantigens
that are abundant in the entheses and amino acid sequences of Klebsiella pneumoniae-derived
proteins suggest a possible link through a molecular mimicry mechanism, as already reported
[13]. The presence of antibodies directed against autoantigens in AS raises a question about
the role played by such antibodies in the pathogenesis of the disease. Based on the findings in
HLA-B27 transgenic rats, where the presence of CD4+ T cells and antigen-presenting cells
expressing high levels of HLA-B27 seem to be of critical importance in the pathogenesis of the
disease [30], and where a possible pathogenic role seems to be played by non-conventional
HLA-B27 molecules [31], we may suggest that such antibodies reflects the presence of an auto-
immune process and may be of relevance, as biomarkers of the disease.
We currently aim to evaluate the presence of ERAP1 polymorphisms in the patients stud-
ied, and to extend the testing for the presence of identified antibodies in patients from different
countries, to confirm the sensitivity and specificity of the test.
In conclusion, we describe here the identification of an antibody reactivity that was detected
in the vast majority of patients with AS; we aim at defining whether such reactivity is due to a
specific antibody or to different antibodies. In the absence of other disease biomarkers, this
antibody reactivity may represent an interesting tool for the diagnosis of AS.
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